Beijing, China March 22, 2022 Sino Biological, Inc. (Sino Biological or the Company), a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047), which provides biological research reagents and related technical contract research services, is pleased to announce a CRO services partnership with Ainnocence, Inc. of San Jose, California.
ADVERTISEMENT
Dutch autoimmunity specialist Argenx SE has raised $700m to prepare commercialisation of subcutanous efgartigimod as treatment for generalized myasthenia gravis.
Biotechnology is a key market segment for Coherent. We provide innovative solutions for academic research, pharma discovery, translational research, clinical testing, and interventional therapeutics. We support these applications with lasers, laser engines, fibers, and fiber optic components.
TCR-T cell therapy specialist Affini-T Therapeutics Inc. (Seattle, Boston) has raised $175m Series A fnancing co-Led by Vida Ventures and Leaps by Bayer
Bavarian Nordic is to receive up to US$225 and double-digit royalties for granting exclusive Chinese commercialisation rights for MVA-BN® RSV to Nuance Pharma.
In the 1990s, the first clinical IVR systems (Interactive Voice Response Systems) were developed in order to randomise patients over the phone, and later, to dispense drug and resupply sites as well.
The life sciences location of Austria has gained considerable momentum since the founding of the very first Austrian biotech company Intercell at the turn of the millennium. Today the whos who of the biotech sector relies on Austria, in particular on its capital city of Vienna.
The development of a sustainable bio-based economy will lead to disruptive economic changes. Venture capitalists focused on targets to drive digitisation in the past are now moving their attention to the bioeconomy
The development of a sustainable bio-based economy will lead to disruptive economic changes. Venture capitalists focused on targets to drive digitisation in the past are now moving their attention to the bioeconomy